# OnCo record brentuximab-vedotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/brentuximab-vedotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "brentuximab-vedotin" ;
  schema:name "Brentuximab vedotin"@en ;
  schema:description "The ADC that made the modern field credible (2011), for Hodgkin lymphoma and CD30+ lymphomas."@en ;
  schema:url <https://onco.cc/drugs/brentuximab-vedotin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Brentuximab_vedotin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q422324> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Brentuximab%20vedotin>, <https://doi.org/10.1038/nrc2542> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Adcetris" ;
  onco:approval "US 2011: Relapsed Hodgkin lymphoma and systemic ALCL", "US 2018: First-line stage III/IV Hodgkin lymphoma with AVD" ;
  onco:acceleratedApproval "US 2011-08-19: Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or after failure of at least 2 multi-agent chemotherapy regimens in patients who are not ASCT candidates", "US 2011-08-19: Systemic anaplastic large cell lymphoma after failure of at least one multi-agent chemotherapy regimen" ;
  onco:acceleratedApprovalConfirmed "US 2015-08-17: Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or after failure of at least 2 multi-agent chemotherapy regimens in patients who are not ASCT candidates", "US 2018-03-20: Systemic anaplastic large cell lymphoma after failure of at least one multi-agent chemotherapy regimen" ;
  onco:related <https://onco.cc/biomarkers/cd30-expression/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/> ;
  onco:terms <https://onco.cc/terms/mc-vc-pabc/> ;
  onco:trials <https://onco.cc/trials/nct04404283/>, <https://onco.cc/trials/nct02979522/>, <https://onco.cc/trials/nct05673785/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/> .